Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 7/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.74 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.74 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.64 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.64 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5248370 | 0.87 | HTR3A (0.77) | HTR3AKCNH2CHRNA7CHRM4CHRM5 | |
| SCHEMBL5531947 | 0.86 | KCNH2 (0.76) | HTR3AKCNH2CHRNA7CHRM4CHRM5 | |
| SCHEMBL5251981 | 0.85 | HTR3A (1.00) | HTR3AKCNH2CHRNA7CHRM4CHRM5 | |
| SCHEMBL5246684 | 0.84 | HTR3A (0.64) | HTR3AKCNH2CHRNA7CHRM4CHRM5 | |
| SCHEMBL5250867 | 0.82 | HTR3A (0.69) | HTR3AKCNH2CHRNA7CHRM4CHRM5 | |
| SCHEMBL5531588 | 0.81 | HTR3A (0.68) | HTR3AKCNH2CHRNA7CHRM4CHRM5 | |
| SCHEMBL5909611 | 0.81 | HTR3A (0.68) | HTR3AKCNH2CHRNA7CHRM4CHRM5 | |
| SCHEMBL5909613 | 0.81 | HTR3A (0.68) | HTR3AKCNH2CHRNA7CHRM4CHRM5 | |
| SCHEMBL5249484 | 0.80 | HTR3A (0.67) | HTR3AKCNH2CHRNA7CHRM4CHRM5 | |
| SCHEMBL5251773 | 0.79 | HTR3A (0.88) | HTR3AKCNH2CHRNA7CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060166974-A1 | Azabenzoxazoles for the treatment of CNS disorders | PFIZER INC. | 2006-07-27 | — | — | US | claimed |
| EP-1831683-A1 | METHODS OF MODULATING THE ACTIVITIES OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR | Pfizer Products Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1814887-A1 | AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS | Pfizer Products Incorporated (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060166974-A1 | Azabenzoxazoles for the treatment of CNS disorders | PFIZER INC. | 2006-07-27 | — | — | US | disclosed |
| US-20060142349-A1 | Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor | PFIZER INC | 2006-06-29 | — | — | US | disclosed |
| WO-2006067611-A1 | METHODS OF MODULATING THE ACTIVITIES OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006051407-A1 | AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166974-A1 | Azabenzoxazoles for the treatment of CNS disorders | CHRNA7, CHRNA5, CHRNA10 | HTR3A 316/4885KCNH2 2357/4885CHRNA7 1/4885 |
| US-20060142349-A1 | Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor | CHRNA7, CHRNA5, CHRNA4 | HTR3A 238/4885KCNH2 451/4885CHRNA7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.